Mr. Christopher Barnes reports

SERNOVA INVESTOR CONFERENCE CALL PREVIOUSLY SCHEDULED FOR SEPTEMBER 15 NOW RESCHEDULED FOR SEPTEMBER 22

Sernova Corp. has rescheduled the investor and analyst conference call previously scheduled for Sept. 15 at 10 a.m. Eastern Time. The call will now occur on Sept. 22 at 10 a.m. Eastern Time. The business strategy and update call remains as scheduled for Oct. 5, 2023.

This call will introduce the newly appointed chief executive officer, Cynthia Pussinen, as well as the recently appointed chief business officer, Dr. Modestus Obochi, PhD, MBA, and will discuss the overall vision of both executives to deliver novel medical therapies to patients.

Date:  Friday, Sept. 22, 2023

Time:  10 a.m. Eastern Time

Dial-in:  1-877-704-4453

Conference ID No.:  13741199

A webcast will be available.

About Sernova Corp.

Sernova is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease and blood disorders that include hemophilia A. Sernova is currently focused on developing a functional cure for insulin-dependent diabetes with its lead asset, the Cell Pouch system, a novel implantable and scalable medical device with immune protected therapeutic cells. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova's Cell Pouch system has demonstrated its potential to be a functional cure for people with T1D in a continuing phase 1/2 clinical study at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the University of Miami to shield therapeutic cells from immune system attack with the goal to eliminate the need for chronic, systemic immunosuppression. In May, 2022, Sernova and Evotec entered into a global strategic partnership to develop an implantable off-the-shelf IPSC-based (induced pluripotent stem cells) islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress two additional development programs that utilize its Cell Pouch system: a cell therapy for hypothyroid disease resulting from thyroid gland removal; and an ex vivo lentiviral factor VIII gene therapy for hemophilia A.

We seek Safe Harbor.